滨州市委副书记、市长李春田在演讲中全面介绍了滨州的产业发展、科技创新和开放优势。他表示，滨州已形成五大千亿级产业集群，科创投入强度全省领 先，拥有良好的开放平台和高效政务服务环境，欢迎德国特别是北威州企业深度参与滨州的产业转型与国际合作，共享发展新机遇。 圆桌讨论环节由北威州国际商务署驻华首席代表封兴良主持，拜耳集团中国公共政府事务与可持续发展高级总监白晨曦、敦豪集团公共事务副总裁陈艳、魏 桥德国有限责任公司总经理何蓉、德国电信DETECON合伙人兼高级总监欧玮明、青岛中德生态园对德交流顾问狄沛、汉高集团中国政府关系与公共事务负 责人于江就双边经贸合作展开深入交流。讨论中，封兴良引导嘉宾们就中德企业在经贸合作和数字化转型等领域的合作机遇展开积极交流。嘉宾们表示，尽 管存在"China+1"供应链调整现象，但一致认为中国在新能源、医药创新等领域的优势仍吸引德企深耕，并强调中国市场的消费潜力与完整产业链具有不可 替代性。对于下半年德国高层的访华计划，嘉宾们也表示期待，并希望借此机会可以进一步优化双边经贸合作机遇，中德两国在产业互补性和技术创新方面 具有广阔的合作前景。 本次论坛由北威州国际商务署华东华中西南大区主 ...

Core Insights - Startup Genome's "Global Startup Ecosystem Report 2025" ranks Silicon Valley first, with New York, London, and Tel Aviv following in second to fourth places, while Beijing rises three spots to tie for fifth with Boston, becoming the only Chinese city in the global top five [1][2] Group 1: Performance Metrics - Beijing ranks third globally in performance metrics, fourth in talent and expertise, and fourth in knowledge supply [1] - Beijing's ecosystem value from 2022 to 2024 is projected at $533 billion, significantly higher than the global average of $204 billion [1] - The number of active unicorns in Beijing is 61, compared to a global average of 4 [1] Group 2: Financial Indicators - Software engineer salaries in Beijing are expected to reach $53,500 in 2024, slightly above the global average of $52,000 [1] - Total venture capital in Beijing from 2020 to 2024 is estimated at $64 billion, while the global average is $5.2 billion [1] Group 3: Supporting Factors - The report attributes Beijing's entrepreneurial ecosystem success to strong government support, top-tier universities, and a thriving capital market [2] - Beijing is recognized as a leading technology and innovation center, particularly in AI-driven data analysis, life sciences, and fintech [2] Group 4: Other Chinese Cities - Other Chinese cities included in the report are Shanghai (10th), Shenzhen (17th), Hangzhou (23rd), Hong Kong (27th), and Guangzhou (35th), with all cities except Hong Kong showing improved rankings [2]

瑞财经 严明会 近日，据港交所官网，安序源科技Axbio International Limited（以下简称"安序源"）在港交所递交招股书，拟在香 港主板挂牌上市，中金公司和浦银国际担任联席保荐人。 招股书显示，安序源成立于2016年，作为全球集成电路生物科技的领导者，致力开发新一代电化学检测平台以实现生命科学工具 及诊断产业的革新。公司融合了集成电路、生物科技及人工智能技术，致力于为生命科学研究及临床应用打造先进的基础平台。 | | 截至12月31日止年度 | | | --- | --- | --- | | | 2023年 | 2024年 | | | (千美元) | | | 收入 | - | 479 | | 销售成本 | - | (175) | | 毛利 | - | 304 | | 其他收入 | 1,935 | 2,063 | | 其他收益及虧損 | (1,477) | (7,805) | | 研發開支 | (15,291) | (11,412) | | 行政開支 | (7,919) | (6,526) | | 融資成本 | (104) | (90) | | 除税前虧損 | (22,856) | (23, ...

编译丨王聪 编辑丨王多鱼 排版丨水成文 饶毅 教授是中国科学和教育领域的杰出改革者。1980 年代，饶毅在美国开启职业生涯，2007 年，他辞去美国西北大学终身教职，全职回国，出任北京大学生命 科学学院院长，他引入了多项举措，使中国生命科学研究重焕生机，其中包括采用终身教职制度和同行评审来评估学者的学术成就。如今， 饶毅 卸任了首都医学 大学校长职务，在北京大学负责一个前沿脑科学研究实验室，并担任其他领导职务。 饶毅 一向以直言不讳著称。2008 年，他放弃美国护照，以抗议前总统乔治·W·布什在 9·11 事件后推行的政策。他还在新冠疫情期间批评了美国的政策，并强 烈反对实验室泄漏论。此外，他还是中国人才引进计划的积极倡导者。 2025 年 6 月 17 日，国际顶尖学术期刊 Nature 发布了一篇对 饶毅 教授的专访 ， Nature 向饶毅询问了他如何看待中国在生命科学领域的作用，以及中国怎样 才能成为生物科技超级大国。 饶毅 教授 中国如何能成为生物科技超级大国？ Nature ：根据《自然》指数，中国在生命科学领域的实力不如在物理科学领域。这是为什么呢？ 只要中国没有类似于美国 NIH 这样的机构， ...

利用光电镊及全自动微流控芯片原理，在实现高通量的同时，节省人工及耗材成本，将不同细胞筛选实验的周期从2-3个月缩短至1-2周。支 持细胞片上原位培养和两个孔板培养，实现全流程自动化；简洁直观的图形操控界面设计和流程步骤选择，轻松实现测试流程自定义；对细胞 全生命周期进行实时全程监控，表征分子以及细胞间的相互作用，不损失细胞活力，得到高质量产出的同时提高实验效率和数据可重现性；对 各个环节拍照成像、数据归档，便于后续溯源。符合GMP设计，自动试剂液位检测、耗材更换和进样针检测和报警。可根据实验室空间选择台 式或立式设备配置，最大限度节省空间；提供正压或负压操作环境，符合ISO Clas s 5等级或BSC Clas s I I生物安全等级。 O p t oBo t ® 1 0 0 0 单 细 胞 光 电 微 流 控 系 统 导读： 本轮募集的资金主要用于追光生物光电微流控产品线的技术升级、生物微机电系统的开发应用以及市场营销网络拓展和服务应用体系完善，推动高端生命 科学仪器的国产化进程。 特别提示 微信机制调整，点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我们的推送。 近日， ...

证券研究报告 | 2025年06月15日 港股市场速览 优于大市 大盘高位震荡，行业分化明显 本周，恒生指数涨 0.4%，恒生科技跌 0.9%。风格方面，小盘（恒生小型股 +4.5%）＞中盘（恒生中型股+3.9%）＞大盘（恒生大型股+0.2%）。 概念指数涨跌互现，涨幅居前的有：恒生创新药（+10.6%）、恒生高股息 （+3.2%）；跌幅居前的有：恒生汽车（-3.1%）。 港股通行业中，19个行业上涨，11个行业下跌。上涨的主要有：综合（+19.2%）、 医药（+8.5%）、国防军工（+8.1%）、有色金属（+6.6%）、电力设备及新 能源（+4.7%）；下跌的主要有：汽车（-4.4%）、食品饮料（-3.5%）、电 子（-2.0%）、家电（-1.9%）、消费者服务（-1.8%）。 资金强度：资金大幅流出汽车板块权重股 本周，资金总体流出港股通成分股，总体日均资金强度（日均涨跌 x 日均 成交量）为-8.0 亿港元/日，上周为+7.4 亿港元/日，近 4 周平均为+2.2 亿 港元/日；近 13 周为-0.3 亿港元/日。 分行业看，20 个行业资金流入，10 个行业资金流出。资金流入的主要有： 医药（+4.8 ...

ONS经济统计主管Liz McKeown指出，服务业和制造业产出的减少是导致4月份整体GDP下滑的主要原 因。她还提到，在过去的三个月里，尽管4月份的数据不佳，但总体GDP仍有所增长，这可能是因为一 些商业活动被提前到了年初完成。 此外，4月份法律和房地产行业的表现尤其疲软。这可能是由于在3月份印花税调整后，购房需求集中释 放，导致4月份的需求相对减弱。这种情况表明，短期经济波动有时会受到政策变动的影响，而这些影 响可能会导致某些行业出现周期性的起伏。 （文章来源：新华财经） 财政大臣Rachel Reeves 对这一数据表示失望，但同时强调其即将进行的支出审查计划将有助于推动经 济增长。 英国政府表示，将加大相关领域的政府投资，并以此带动私人投资，从而实现经济增长。未来五年内， 英国将投入156亿英镑，用于改善城市交通基础设施。将在今后几年内投资860亿英镑，用于加速推动英 国增长最快的行业，包括科技、生命科学、先进制造业和国防等。将投入1.87亿英镑，用于学生AI方面 的培训，其中的0.24亿英镑，将作为该项目的旗舰项目的投资，目的是让英国每所中学的学生有机会在 三年内获得新的人工智能技能。到2027年， ...

丨证券研究报告丨 行业研究丨专题报告丨制药、生物科技与生命科学 [Table_Title] IL-25：II 型炎症通路创新靶点，剑指百亿美元特 应性皮炎市场 报告要点 [Table_Summary] IL-25 为 II 型炎症通路细胞因子，研究发现其在特应性皮炎 (AD)、银屑病和接触性皮炎这几种 皮肤炎症疾病的病变组织中均有上调，表明其与这几种疾病的发展有关。由中国抗体开发的 SM17 是全球 FIC 的 IL-25 受体 IL-17RB 单抗，针对特应性皮炎（AD）的 Ib 期顶线数据展现 出了优异的 PoC 数据，在保证不弱于 IL-4 单抗等疗法的皮损改善能力前提下，实现了比现有 创新疗法更快速和深度的瘙痒改善，有望成为特应性皮炎市场的下一个重磅靶点，并且还具有 拓展至其他 II 型炎症适应症的潜力。 分析师及联系人 [Table_Author] 彭英骐 刘长洪 SAC：S0490524030005 SFC：BUZ392 请阅读最后评级说明和重要声明 %% %% %% %% research.95579.com 1 制药、生物科技与生命科学 cjzqdt11111 [Table_Title2] I ...

Summary of Bio Techne Conference Call Company Overview - **Company**: Bio Techne - **Analyst**: Matt Sykes, Goldman Sachs - **CFO**: Jim Hipple - **Head of IR**: David Claire Key Highlights from Fiscal Q3 Results - **Overall Growth**: Achieved 6% organic growth in Q3 despite macroeconomic headwinds [5][6] - **Protein Sciences Segment**: Notable 7% growth, driven by widespread demand across core reagents and instrument platforms [5][6] - **Large Pharma Market**: Contributed significantly to growth, accounting for 30% of total revenue, with double-digit growth observed [6][7] U.S. Academic Market Insights - **Revenue Contribution**: U.S. academic customers represent approximately 12% of total revenue [12] - **Market Volatility**: Academic market has been volatile due to budget cuts and NIH funding fluctuations, but core reagents remain stable [10][11] - **International Exposure**: Academic markets outside the U.S., particularly in Europe, have shown robust growth, helping to stabilize overall academic revenue [14] Tariff Exposure and Mitigation - **Manufacturing Resilience**: Most products manufactured in the U.S., with core reagents exempt from tariffs, minimizing exposure [16][17] - **Mitigation Strategies**: Ability to ramp up production in non-China facilities to avoid tariff impacts [18] China Market Performance - **Revenue Impact**: China accounts for about 8% of total revenue, with recent quarters showing negative mid-single-digit growth [20][21] - **Customer Sentiment**: A slight shift towards optimism among customers in China, indicating potential for future growth [22][23] Biopharma Market Dynamics - **Market Segmentation**: Distinction between large pharma and biotech, with large pharma showing more stability and less volatility [26][27] - **R&D Budgets**: Anticipated increases in R&D budgets for large pharma in 2025, despite recent caution due to external factors [28][30] Instrumentation and Consumables - **Growth in Instrumentation**: Achieved upper single-digit growth in instrumentation, driven by strong consumable pull-through [43][44] - **Competitive Advantage**: Unique product offerings with minimal direct competition in key instrument platforms [45][46] GMP Reagents and Cell & Gene Therapy - **Revenue Dynamics**: Growth in GMP reagents is lumpy due to reliance on clinical trial purchases, but reflects progress in customer development [50][52] - **Wilson Wolf Acquisition**: Bio Techne owns 20% of Wilson Wolf, with plans to acquire the remaining 80% based on performance metrics, enhancing growth potential in cell therapy [62][65] Spatial Biology and Diagnostics - **Market Position**: Bio Techne is a leading player in spatial biology, with a focus on translational applications and a profitable business model [67][68] - **COMET Platform**: New automated solution for spatial biology, capable of multi-omic detection, enhancing reagent pull-through [69][70] Financial Outlook - **Q4 Expectations**: Anticipating low single-digit growth due to continued market challenges, particularly in large pharma [73][75] - **Margin Projections**: Expected decline in operating margins due to tariff impacts, but viewed as a temporary issue [76][77] Capital Allocation Strategy - **Share Repurchase Plan**: Announced a $500 million share repurchase plan, indicating confidence in company valuation and a tactical approach to capital allocation [78][81] - **M&A Strategy**: Continued focus on M&A as a key growth strategy, particularly targeting private companies [80][82]

Revvity (RVTY) FY Conference Summary Company Overview - **Company**: Revvity (formerly PerkinElmer) - **Industry**: Life Sciences Tools and Diagnostics Key Points and Arguments Market Environment and Company Adaptation - The current market is dynamic with uncertainties due to policy changes, tariffs, and challenges in pharma, biotech, and academia sectors [3][4][5] - Revvity's diverse portfolio has demonstrated resilience amidst these challenges, with 60% of revenue now coming from diagnostics and software [4][5][8] Financial Performance and Growth - Revvity's growth rate is at the top end of its publicly traded peer group, with a long-range plan (LRP) growth target of 6-8%, compared to 3-5% previously [4][7] - The company has shifted to a recurring revenue model, with over 80% of revenue now from recurring sources, improving margins from 18-20% to 28% [7][8] - Organic growth guidance for the year is set at 3-5%, with confidence in achieving this despite market uncertainties [9][12] Life Sciences Segment Challenges - The life sciences segment faces challenges due to funding shifts towards clinical work, impacting preclinical discovery [14][15] - Revvity's differentiated product portfolio in consumables is expected to maintain growth despite these challenges [15][20] Software Business - Revvity's software business is unique, functioning as an ERP for researchers, with 48 out of the top 50 pharma companies using its software [26][28] - The software segment is expected to grow significantly, contributing to overall margin improvement [56] Diagnostics and Growth Opportunities - Immunodiagnostics represent a significant growth opportunity in the U.S., with current market penetration at 15-20% compared to a historical 35-40% [30][31] - The company is focusing on expanding its offerings in reproductive health and rare disease testing, leveraging partnerships for growth [40][41] Competitive Landscape in China - Revvity faces intense competition in China, but differentiates itself through proprietary assays and a focus on complex diseases [35][36] - The company is adapting to local market conditions and regulatory environments to maintain growth and profitability [36][39] Capital Allocation and M&A Strategy - Revvity has been active in M&A, completing 13 acquisitions in 22 months to enhance its portfolio [60][62] - Current capital allocation focuses on share buybacks, with a balanced approach to future M&A opportunities [64][68] Long-term Outlook - The company aims for mid-30s operating margins in a normalized market environment, with equal opportunities for margin expansion across life sciences and diagnostics [54][56] - Revvity's strong portfolio and execution strategy position it well for long-term growth despite current macroeconomic challenges [72][74] Additional Important Insights - The company emphasizes innovation and automation in its product offerings to enhance researcher productivity, especially in a budget-constrained environment [47] - Revvity's software and diagnostics segments are seen as critical to its long-term success, with ongoing efforts to improve customer stickiness and market penetration [25][28][70]